Skip to content

Neuro Imaging and Multimodal Alzheimer's Disease

Neuro Imaging and Multimodal Alzheimer's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02839187
Acronym
NIMAD
Enrollment
59
Registered
2016-07-20
Start date
2010-06-30
Completion date
2012-05-31
Last updated
2017-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

The present study aimed at measuring cerebral changes in Alzheimer Disease (AD) patients, who responded to strict physiological criteria typical of AD pathology. The objective of the present study was to identify the earliest alterations in cerebral connections that could contribute to the initial episodic memory impairment.

Interventions

RADIATIONNeuroimaging

AV45-positron emission tomography

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

For all subjects : * Capacities visual, auditory (authorized devices) and oral or written expression sufficient for the proper performance of tests * Obtain informed written consent of the subject Patients with AD : * Outpatient accompanied by a helping * No parenchymal lesions allowing isolation explain the symptoms on brain MRI (T1 and T2) carried more than 6 months prior to enrollment in the study. Patients with more than three hyperintense white matter or visible lacunar infarction or T2 FLAIR will not be included in the study. * probable Alzheimer's disease diagnosis par with international standards * Illness in a mild stage (CDR 1, 24 ≥ Mini-Mental State Examination (MMSE)\> 18) * activity of daily living (ADL) 4 items\> 1/4 Patients with Alzheimer's disease at a pre-dementia stage: * Alzheimer's Diagnosis pre-dementia based on the search criteria * Illness in a mild stage (CDR 0.5, 30 ≥ MMSE ≥ 25) * ADL items ≤ 4 1/4 Control subjects : * 30 ≥ MMSE ≥ 27 * perfect autonomy in daily living (IADL = 0, CDR = 0) * Neuropsychological evaluation not highlighting of impaired cognitive performance with focus on memory performance * No parenchymal lesions on brain MRI. * Lack of family history (first degree) of Alzheimer's disease

Exclusion criteria

* Subjects with a contra-indication to MRI (carrying a pacemaker or cardiac defibrillator, implanted a material activated by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral aneurysms or carotid artery , holders of orthopedic implants, claustrophobia) * Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular * Subjects with a psychiatric disorder or progressive neurological * French Language level insufficient to be appropriately involved in neurophysiological evaluation * less than 5 years Education (insufficient understanding level to participate in the study) * Administrative problems: unable to give informed about information, not covered by a social security system * Hypersensitivity to the active substance or to any of the excipients * unbalanced diabetes mellitus * Subjects treated by a non-steroidal anti-inflammatory

Design outcomes

Primary

MeasureTime frameDescription
fixing the AV-45 during PETbaselinecompare fixing the AV-45 during a examination emission tomography (PET) between three different groups: healthy subjects, patients with Alzheimer's disease and a mild stage patients of Alzheimer's disease at a pre-dementia stage

Secondary

MeasureTime frameDescription
Deposition of amyloid proteinbaselineCorrelation between the deposition of amyloid protein assessed by metabolic imaging (AV-45) and cognitive performance in a group of patients with Alzheimer's disease compared to a control group
Standard Cognitive functionBaselineno memory performance: language (OD 80), executive functions (TMT A and B, evocations formal and categorical lexical, Stroop test, Pyramid-palm tree test Visual and Verbal) praxis visuo-constructive (copy of the figure of Rey) ; working memory (span of front and back numbers, subtest of the WAIS code-III)
Specific memory evaluationBaselineanterograde verbal memory (test Gröber and Buschke), memory unique items (visual DMS48), semantic memory (sub-test information of theWechsler Adult Intelligence Scale (WAIS))

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026